Bausch + Lomb Q4 Earnings Review: Still A Buy, With Some Caveats

Impact · against what's priced in

Bausch + Lomb shows strong operational momentum with significant EBITDA growth and a clear revenue floor through 2028. The results confirm the company's ability to scale profitability relative to its organic growth.

BLCO+0.60

No priced-in read yet

In context

The company's 27% adjusted EBITDA growth against 7% constant currency revenue growth demonstrates strong operating leverage and a clear path to profitability.

Read from the article alone

• earnings▲2%
• healthcare
• guidance
• revenue growth
• BLCO
• medical devices
• profitability

Top 1 mover · tap to explore